184 related articles for article (PubMed ID: 17384216)
1. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.
Cheung IY; Feng Y; Vickers A; Gerald W; Cheung NK
J Mol Diagn; 2007 Apr; 9(2):237-41. PubMed ID: 17384216
[TBL] [Abstract][Full Text] [Related]
2. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.
Cheung IY; Vickers A; Cheung NK
Int J Cancer; 2006 Jul; 119(1):152-6. PubMed ID: 16450393
[TBL] [Abstract][Full Text] [Related]
3. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
[TBL] [Abstract][Full Text] [Related]
4. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.
Cheung IY; Feng Y; Gerald W; Cheung NK
Clin Cancer Res; 2008 Nov; 14(21):7020-7. PubMed ID: 18980998
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
Kuroda T; Saeki M; Nakano M; Mizutani S
J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
[TBL] [Abstract][Full Text] [Related]
6. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
7. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
[TBL] [Abstract][Full Text] [Related]
8. Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma.
Brizova H; Kalinova M; Krskova L; Mrhalova M; Kodet R
Int J Cancer; 2008 Dec; 123(12):2865-70. PubMed ID: 18798551
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.
Cheung NK; Ostrovnaya I; Kuk D; Cheung IY
J Clin Oncol; 2015 Mar; 33(7):755-63. PubMed ID: 25559819
[TBL] [Abstract][Full Text] [Related]
10. The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma.
Oltra S; Martinez F; Orellana C; Grau E; Fernandez JM; Cañete A; Castel V
Diagn Mol Pathol; 2005 Mar; 14(1):53-7. PubMed ID: 15714065
[TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.
Lokvenc M; Kalinova M; Forsterova K; Klener P; Trneny M; Fronkova E; Kodet R
Ann Hematol; 2018 Mar; 97(3):467-474. PubMed ID: 29273915
[TBL] [Abstract][Full Text] [Related]
12. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
13. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
Cheung IY; Cheung NK
Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
[TBL] [Abstract][Full Text] [Related]
16. Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Ora I; van Sluis PG; Bras J; den Ouden E; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Mol Diagn; 2012; 14(2):168-75. PubMed ID: 22251610
[TBL] [Abstract][Full Text] [Related]
17. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
[TBL] [Abstract][Full Text] [Related]
18. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.
Yue Z; Gao C; Xing T; Zhao W; Duan C; Wang X; Jin M; Su Y
Pediatr Blood Cancer; 2023 May; 70(5):e30261. PubMed ID: 36815592
[TBL] [Abstract][Full Text] [Related]
19. Elevated nuclear CCND1 expression confers an unfavorable prognosis for early stage lung adenocarcinoma patients.
Xu P; Zhao M; Liu Z; Liu Y; Chen Y; Luo R; Fang W
Int J Clin Exp Pathol; 2015; 8(12):15887-94. PubMed ID: 26884860
[TBL] [Abstract][Full Text] [Related]
20. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Yalcin B; Dee R; van Noesel MM; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Clin Chem; 2009 Jul; 55(7):1316-26. PubMed ID: 19460840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]